SCHEMBL4939446

SCHEMBL4939446

Cc1cnoc1-c1cccc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.53
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
ESR2 Q92731 1/20 0.45
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
TP53 P04637 2/20 0.42
MAPT P10636 1/20 0.42
CYP19A1 P11511 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
IDO1 P14902 3/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MGAM O43451 1/20 0.41
GAA P10253 1/20 0.41
SI P14410 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15428657 0.79 TDO2 (0.61) TDO2NPC1RAB9ATP53IDO1
SCHEMBL10166453 0.77 CYP19A1 (0.53) TDO2PTGS1PTGS2NPC1RAB9A
SCHEMBL5776120 0.76 TDO2 (0.49) TDO2PTGS1PTGS2NPC1RAB9A
SCHEMBL3178747 0.74 NPC1 (0.50) TDO2NPC1RAB9ATP53MAPT
SCHEMBL5775490 0.73 ALOX5 (0.52) TP53MAPTCYP2C9CYP2C19SMN1; SMN2
SCHEMBL6170416 0.72 PTGS1 (0.60) TDO2PTGS1PTGS2NPC1RAB9A
SCHEMBL5774842 0.71 TDO2 (0.44) TDO2MAPTPTPN2PTPN1NOTUM
SCHEMBL9953638 0.69 NOTUM (0.47) PTGS1PTGS2ESR2NPC1RAB9A
SCHEMBL5546758 0.69 ALDH1A1 (0.48) PTGS1PTGS2ESR2NPC1RAB9A
SCHEMBL9954839 0.69 NPC1 (0.45) PTGS1PTGS2ESR2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456200-B2 Compounds ASTRAZENECA AB (SE) 2008-11-25 US disclosed
US-20060122397-A1 Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain ASTRAZENECA AB (SE) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122397-A1 Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain GRM5, GRIK5, GRM1 TDO2 4395/4885PTGS1 290/4885PTGS2 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.